New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AKR;MCD;MPEL;SYT;RHHBY;TSM;DST;AET;ATHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
December 19, 2014
16:31 EDTRHHBYOn The Fly: Closing Wrap
Subscribe for More Information
12:27 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
11:32 EDTRHHBYRoche acquires privately held Bina Technologies
Subscribe for More Information
09:48 EDTRHHBYBiogen should be bought on weakness after Roche drug halted, says Evercore ISI
Subscribe for More Information
09:28 EDTRHHBYOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTMPELMelco Crown identified as top 2015 gaming pick at Sterne Agee
Subscribe for More Information
08:53 EDTRHHBYBiogen drug, trial differs from Roche Alzheimer's drug, says RBC Capital
Subscribe for More Information
08:51 EDTRHHBYBiogen drops 2% after Roche discontinues Alzheimer drug trial
Shares of Biogen (BIIB) are moving lower after Roche (RHHBY) announced the discontinuation of its Alzheimer's drug gantenerumab, which was in Phase III testing. Analysts at Wells Fargo said Roche's trial failure adds risk to Biogen's potential treatment of Alzheimer's. Shares of Biogen are down $8.20 to $345.50 in pre-market trading.
06:12 EDTMCDMcDonald's implied volatility of 25 at upper end of index mean range
06:12 EDTRHHBYRoche says breast cancer study did not meet PFS superiority endpoint
Subscribe for More Information
06:10 EDTRHHBYRoche to discontinue Phase III study of Alzheimer's disease drug
Roche announced the decision to discontinue SCarlet RoAD, a phase III study of investigational anti-amyloid medicine gantenerumab in prodromal Alzheimer’s disease, based on results of a pre-planned futility analysis and recommendation by the independent Data Monitoring Committee. No new safety signals for gantenerumab were observed in this analysis and the overall safety profile was similar to that seen in the phase I trial, Roche said. Data from the SCarlet RoAD study will be shared with the medical community after full review and analysis, it added. "We are disappointed with these study results because people with early stage Alzheimer's need new medicines that delay disease progression,” said Sandra Horning, M.D., Chief Medical Officer at Roche. "This is the first Phase III trial to evaluate a potential disease-modifying medicine in this early prodromal stage of Alzheimer’s disease. We remain committed to investigating new medicines for this devastating illness."
05:36 EDTRHHBYImmunoGen reports Phase III MARIANNE study met non-inferiority endpoint
Subscribe for More Information
05:33 EDTRHHBYGenentech provides update on Phase III MARIANNE
Subscribe for More Information
December 18, 2014
12:46 EDTRHHBYRoche acquires privately held Dutalys for $133.75M up front
Roche announced that it has agreed to acquire Dutalys GmbH, a privately held biotechnology company based in Vienna, Austria. Dutalys specializes in the discovery and development of fully human, bi-specific antibodies based on their proprietary DutaMab technology, Roche said. Under the terms of the agreement, Roche will make an upfront cash payment of $133.75M to shareholders and make additional contingent payments of up to $355M based on the achievement of certain predetermined milestones.
11:08 EDTMCDOptions with increasing implied volatility
Options with increasing implied volatility: CZR RSX HLF YPF ARCP MGM A MCD
December 17, 2014
12:03 EDTMCDMcDonald's higher after Ackman offers 'no comment' on rumor of investment
Subscribe for More Information
11:47 EDTMCDMcDonald's spikes higher, moderates, levels to watch
On a five day chart the last two consecutive days of low activity, a sudden price spike, and a moderation in price is quite evident. Those spikes are accompanied by extremely heavy volume, which has then faded. And interestingly the timing of the spikes, beginning at 10:45am ET, has been the same in both sessions. With price last at $90.47, next resistance is at $91.86, the session high. Support is at $89.96.
11:09 EDTMPELMacau gaming facts in SCMP article are not new, says JPMorgan
Subscribe for More Information
11:02 EDTMCDMcDonald's volatility increases on Ackman offers no comment on rumor
Subscribe for More Information
10:57 EDTMCDMcDonald's jumps after Ackman offers no comment on rumor
Subscribe for More Information
10:52 EDTMCDAckman says can't comment on rumor of McDonald's stake
Subscribe for More Information
10:51 EDTAETLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Gupte provides outlook and favorite names for 2015 in the Hospitals and Managed Care Industry on an Analyst/Industry conference call to be held on December 18 at 1 pm.
10:36 EDTATHNOptions with decreasing implied volatility
Subscribe for More Information
December 16, 2014
16:00 EDTMCDOptions Update; December 16, 2014
iPath S&P 500 VIX Short-Term Futures up 1.55 to 34.60. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX AA MGM MCD according to Track Data.
15:37 EDTMPELChina to start crackdown on illicit funds to Macau, SCMP says
Subscribe for More Information
14:02 EDTMCDMcDonald's rises amid rumor of Ackman taking activist stake
Subscribe for More Information
12:56 EDTSYTSyngenta corn reportedly approved in China, Agri-Pulse says
Subscribe for More Information
10:55 EDTMCDMcDonald's spikes higher, levels to watch
Subscribe for More Information
10:48 EDTMCDRumor: McDonald's moving up amid activist investor speculation
Subscribe for More Information
10:34 EDTATHNOptions with decreasing implied volatility
Options with decreasing implied volatility: TLM LE CIEN LULU RH ATHN PAY
08:47 EDTRHHBYHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
05:46 EDTRHHBYRoche launches PCR molecular diagnostic system for point of care environment
Subscribe for More Information
December 15, 2014
11:32 EDTATHNathenahealth removed from short-term buy list at Deutsche Bank
10:23 EDTATHNOptions with decreasing implied volatility
Options with decreasing implied volatility: LE CIEN LULU PETM RH ATHN ADBE
08:40 EDTTSMCLSA technology analysts hold a luncheon meeting
Subscribe for More Information
05:24 EDTRHHBYExelixis announces Genentech files NDA for cobimetinib, vemurafenib combination
Exelixis (EXEL) announced its collaborator Genentech, a member of the Roche Group (RHHBY), has completed the filing of its New Drug Application, or NDA, with the FDA for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year. The NDA is based on data from the coBRIM trial, a phase 3 pivotal trial conducted by Genentech in 495 patients with BRAF V600 mutation-positive unresectable locally advanced or metastatic melanoma.
December 12, 2014
16:33 EDTMCDStocks finish week lower amid steep decline in oil prices
Subscribe for More Information
13:52 EDTAETLeerink healthcare services analyst holds an analyst/industry conference call
Subscribe for More Information
11:01 EDTATHNOptions with decreasing implied volatility
Subscribe for More Information
09:03 EDTAKRAcadia Realty Trust 3.4M share Spot Secondary priced at $31.75
Subscribe for More Information
08:46 EDTAETAetna price target raised to $103 from $92 at Credit Suisse
Credit Suisse raised Outperform rated Aetna's price target to $103 based on updated guidance and longer term growth opportunities.
08:03 EDTAETAetna 2015 EPS guidance cautious, says Wells Fargo
Subscribe for More Information
05:52 EDTRHHBYRoche announces retirement of Genentech research head
Subscribe for More Information
December 11, 2014
18:14 EDTAKROn The Fly: After Hours Movers
Subscribe for More Information
16:30 EDTATHNOn The Fly: Closing Wrap
Subscribe for More Information
16:14 EDTAKRAcadia Realty Trust files to sell 3.4M common shares of beneficial interest
Citigroup is acting as the sole bookrunner for the offering.
09:05 EDTTSMTSMC reports November sales down 10.5% to $2.32B, DigiTimes reports
Subscribe for More Information
08:50 EDTAETAetna sees operating EPS highest in 1Q15
Subscribe for More Information
08:41 EDTATHNathenahealth price target lowered to $110 from $120 at FBR Capital
Subscribe for More Information
06:32 EDTTSMGlobalfoundries hope to win orders from Qualcomm and Apple, DigiTimes reports
Subscribe for More Information
December 10, 2014
17:04 EDTAETAetna sees FY15 operating EPS at least $6.90, consensus $7.17
Sees FY15 operating revenue at least $62B, consensus $61.68B. Guidance to be confirmed at investor conference in New York on December 11.
17:02 EDTAETAetna backs FY14 operating EPS $6.60-$6.70, consensus $6.68
Subscribe for More Information
16:09 EDTATHNathenahealth says will invest in FY15 to support 30% booking growth goal
athenahealth said that in FY15, the company plans to continue to scale its operations and improve Non-GAAP Adjusted Gross Margin; plans to continue to invest in sales and marketing to support its bookings growth goal of 30%; plans to increase investment in research and development to support building its continuum of care services; and plans to scale general and administrative expenses overall, while strategically investing in select areas.
16:07 EDTATHNathenahealth sees FY15 adjusted EPS $1.20-$1.30, consensus $1.25
Subscribe for More Information
16:05 EDTATHNathenahealth backs FY14 EPS close to high end of 98c-$1.10, consensus $1.10
Subscribe for More Information
16:00 EDTMCDOptions Update; December 10, 2014
Subscribe for More Information
14:51 EDTMCDMcDonald's to offer fewer food items, Reuters reports
Subscribe for More Information
14:45 EDTAETDeal would block payments to health insurance companies, The Hill says
Subscribe for More Information
12:04 EDTSYTUSDA lowers 2014/15 soybean ending stock forecast
Subscribe for More Information
11:10 EDTATHNathenahealth added to the short-term buy list at Deutsche Bank
10:56 EDTMCDMcDonald's could test its 52-week low, levels to watch
Subscribe for More Information
07:56 EDTSYTUBS to hold a conference
Agriculture Investor Day is being held in Chicago on December 10.
December 9, 2014
14:22 EDTAETAetna updates clinical policy for H.P. Acthar Gel
Subscribe for More Information
13:06 EDTMPELMelco Crown management to meet with Sterne Agee
Meeting to be held in New York on December 11 hosted by Sterne Agee.
12:22 EDTRHHBYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
09:38 EDTMCDActive equity options trading
Subscribe for More Information
07:44 EDTRHHBYAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
December 8, 2014
16:24 EDTMCDOn The Fly: Closing Wrap
Stocks on Wall Street were lower amid another drop in crude oil prices, which tumbled to five-year lows. The market opened slightly lower following weaker than expected data from China and Japan, with nothing of note on the domestic calendar to get buyers involved in the day’s activity. Near noon, the averages gained downside momentum and though the market pared its losses several times, it was never able to gain any steam to pull the indexes back into the green. ECONOMIC EVENTS: In the U.S., no major economic data was released. In Asia, Chinese exports rose 4.7% from a year earlier in November, which missed the consensus estimate for an 8% increase. Chinese imports fell 6.7% from the prior year last month, compared with projections for a 3.8% increase. Additionally, Japan's revised third quarter gross domestic product estimate showed the economy shrank more than initially thought, with growth contracting an annualized 1.9%. COMPANY NEWS: Shares of Cubist Pharmaceuticals (CBST) surged $26.24, or 35.29%, to $100.60 after Merck (MRK) agreed to acquire the maker of next-generation antibiotics for $102 per share in cash, or $8.4B and the assumption of $1.1B in debt. A number of other antibiotic makers also climbed, including Tetraphase (TTPH), which rose $2.45, or 8.82%, to $30.24, and Cempra (CEMP), which advanced $1.64, or 11.37%, to $16.06, while shares of Merck finished fractionally higher, adding 39c, or 0.63%, to $61.88 following the deal announcement. MAJOR MOVERS: Among the notable gainers following their presentations at the American Society of Hematology, or ASH, annual meeting were Calithera Biosciences (CALA), which gained $2.38, or 22.52%, to $12.95, and Acceleron Pharma (XLRN), which jumped $5.11, or 13.6%, to $42.67. Among the noteworthy losers was McDonald's (MCD), which fell $3.70, or 3.84%, to $92.61 after the Dow member reported a 2.2% decline in global same-restaurant sales in November. Additionally, the fast-food giant warned that its fourth quarter results would be hurt by its sales pressures, supplier issues in China and a stronger U.S. dollar. Also lower were shares of Liquidity Services (LQDT), which plunged $2.77, or 27.0%, to $7.49 after the company disclosed that Wal-Mart (WMT) had terminated a deal to provide it with surplus merchandise. INDEXES: The Dow fell 106.31, or 0.59%, to 17,852.48, the Nasdaq dropped 40.06, or 0.84%, to 4,740.69, and the S&P 500 slipped 15.06, or 0.73%, to 2,060.31.
12:40 EDTMCDOn The Fly: Midday Wrap
Subscribe for More Information
11:13 EDTATHNathenahealth volatility elevated into investor meeting
Subscribe for More Information
10:08 EDTATHNathenahealth to host investor meeting
Investor meeting to be held in Watertown, MA on December 11 at 8:30 am. Webcast Link
10:08 EDTMCDMcDonald's falls on weak November sales, levels to watch
Subscribe for More Information
10:00 EDTTSMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Buy from Neutral at Citigroup... Apache (APA) upgraded to Buy from Neutral at Citigroup... Applied Materials (AMAT) upgraded to Buy from Hold at Deutsche Bank... Arch Capital (ACGL) upgraded to Outperform from Market Perform at BMO Capital... CU Bancorp (CUNB) upgraded to Buy from Hold at Sandler O'Neill... Calpine (CPN) upgraded to Outperform from Neutral at Macquarie... Commerzbank (CRZBY) upgraded to Market Perform from Underperform at Keefe Bruyette... EastGroup Properties (EGP) upgraded to Neutral from Underperform at Credit Suisse... Enbridge Energy Management (EEQ) upgraded to Equal Weight at Morgan Stanley... Enbridge Energy (EEP) upgraded to Equal Weight from Underweight at Morgan Stanley... GasLog (GLOG) upgraded to Buy from Hold at Stifel... Hoegh LNG (HMLP) upgraded to Buy from Neutral at UBS... Illinois Tool Works (ITW) upgraded to Buy from Accumulate at Global Hunter... LaSalle Hotel (LHO) upgraded at Morgan Stanley... Lufthansa (DLAKY) upgraded to Buy from Neutral at Nomura... NASDAQ (NDAQ) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Citigroup... Omega Healthcare (OHI) upgraded to Buy from Hold at Jefferies... Orange SA (ORAN) upgraded to Conviction Buy from Neutral at Goldman... SM Energy (SM) upgraded to Outperform from Market Perform at BMO Capital... Southwest (LUV) upgraded at Goldman... TSMC (TSM) upgraded to Buy from Neutral at BofA/Merrill... United Technologies (UTX) upgraded at Bernstein... eBay (EBAY) upgraded to Buy from Hold at Stifel.
09:48 EDTMCDMarket begins lower, averages turns mixed in early trade
Stock futures trade below fair value throughout the pre-market trading session, leading to a lower open for the broader market. The Dow finished last week at an all-time high and just slightly below its next milestone level of 18,000, but it continues to be weighed on during early trading from McDonald's (MCD), which is down over 3% following its November sales report. In early trading, the Dow is down 17 points, the Nasdaq is up 7 points and the S&P is down 1 point.
09:38 EDTMCDMcDonald's sees Q4 margins 'significantly pressured' by top-line performance
Subscribe for More Information
09:20 EDTMCDOn The Fly: Pre-market Movers
Subscribe for More Information
07:59 EDTMCDMcDonald's reports November global comparable sales decreased 2.2%
Subscribe for More Information
06:42 EDTMCDMcDonald's coverage resumed with a Neutral at Goldman
Subscribe for More Information
06:13 EDTTSMTSMC upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
December 5, 2014
11:33 EDTRHHBYGenentech to present clinical data at ASH
Subscribe for More Information
09:16 EDTAKRAcadia Realty Trust announces special cash dividend of 30c for 2014
Subscribe for More Information
06:21 EDTAETAetna to host investor meeting
Investor meeting to be held on December 11 at 8:30 am. Webcast Link
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use